Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery - PubMed
5 hours ago
- #Obesity Therapies
- #Metabolic Bariatric Surgery
- #Cardiovascular Disease
- Obesity is an independent driver of cardiovascular disease (CVD), mediated through various adverse pathways.
- Glucagon-like peptide 1 receptor agonists reduce major adverse CV events (MACE) in patients with obesity and established CVD.
- Semaglutide and tirzepatide improve symptoms and functional capacity in obesity-related heart failure with preserved ejection fraction.
- Metabolic bariatric surgery shows durable weight loss and lower rates of MACE, heart failure, and all-cause mortality in observational studies.
- Sustained weight loss of at least 10% is more likely to translate into CVD event reduction.
- Obesity treatments offer safe and effective weight loss with varying CV benefits, though more evidence is needed for robust clinical recommendations.